

Date: 30<sup>th</sup> May, 2025

To,  
**BSE Limited**  
Department of Corporate Services  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400001.  
**Scrip Code: 511523**

**Sub: Outcome of Board Meeting**

Dear Sir,

We would like to inform you that at the Board Meeting held today i.e. May 30, 2025, the Board has approved and taken on record Audited Financial Results for the quarter and year ended March 31, 2025. Further, to conserve resources of the Company, the Board has not recommended any dividend on equity shares of the Company for the financial year ended March 31, 2025.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- 1) Statement showing Audited Financial Results for the quarter and year ended March 31, 2025.
- 2) Auditors Report on the Audited Financial Results for the year ended March 31, 2025.
- 3) Declaration in respect of Audit Report with Unmodified Opinion.

The Board Meeting commenced at 4.00 p.m. and concluded at 5.00 p.m.

Kindly take the above information on record and oblige.

Thanking You.

Yours faithfully,  
For **Veerhealth Care Limited**


Yogesh M. Shah  
Chairman & Director  
DIN: 00169189



**Statement of Audited Financial Results for the Quarter and Year ended March 31, 2025**

(Amount in lakhs)

Sr. No.	Particulars	Standalone				
		Quarter ended 31-03-2025	Quarter ended 31-12-2024	Quarter ended 31-03-2024	Year ended 31-03-2025	Year ended 31-03-2024
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from operations	562.00	383.89	336.72	1667.05	1322.31
II	Other Income	43.37	17.92	16.61	121.87	138.98
III	<b>Total Revenue (I + II)</b>	<b>605.37</b>	<b>401.81</b>	<b>353.33</b>	<b>1788.92</b>	<b>1461.29</b>
IV	Expenses:					
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	436.76	237.35	226.72	1244.81	791.89
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	13.36	27.37	5.86	-104.88	120.97
	(d) Employee benefits expense	34.13	52.88	43.58	157.81	131.03
	(e) Finance Costs	13.76	1.30	0.23	26.39	0.76
	(f) Depreciation and amortisation expense	26.49	25.07	18.14	90.78	71.15
	(g) Other expenses	94.16	50.79	42.98	323.23	217.19
	<b>Total Expenses</b>	<b>618.66</b>	<b>394.76</b>	<b>337.51</b>	<b>1738.14</b>	<b>1332.99</b>
V	<b>Profit/(Loss) before exceptional items (III - IV)</b>	<b>-13.29</b>	<b>7.05</b>	<b>15.82</b>	<b>50.78</b>	<b>128.30</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.16
VII	<b>Profit before tax (V - VI)</b>	<b>-13.29</b>	<b>7.05</b>	<b>15.82</b>	<b>50.78</b>	<b>128.14</b>
VIII	Tax expense:					
	1) Current Tax	-5.71	0.00	12.15	9.29	28.50
	2) Prior Year Tax	-11.31	0.00	0.00	-11.31	0.00
	3) Deferred Tax	13.66	0.00	59.04	13.66	59.04
IX	<b>Profit/(Loss) for the period (VII - VIII)</b>	<b>-9.93</b>	<b>7.05</b>	<b>-55.37</b>	<b>39.14</b>	<b>40.60</b>
X	Other Comprehensive Income					
	(a) Items that will not be reclassified to Profit or Loss	0.00	0.00	4.07	0.00	0.76
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00	0.00
	<b>Other Comprehensive Income</b>	<b>0.00</b>	<b>0.00</b>	<b>4.07</b>	<b>0.00</b>	<b>0.76</b>
XI	<b>Total Comprehensive Income for the period (IX + X)</b>	<b>-9.93</b>	<b>7.05</b>	<b>-51.30</b>	<b>39.14</b>	<b>41.36</b>
XII	Paid-up equity share capital of Rs. 10 each	1999.85	1999.85	1999.85	1999.85	1999.85
XIII	Other Equity				222.03	184.03
XIV	<b>Net Worth</b>				<b>2221.88</b>	<b>2183.88</b>
XV	Earnings Per Share (of Rs. 10 each):					
	(a) Basic (in Rs.)	-0.05	0.04	-0.26	0.20	0.21
	(b) Diluted (in Rs.)	-0.05	0.04	-0.26	0.20	0.21


**VEERHEALTH CARE LIMITED**

**Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.**

**Tel. No. 022-22018582 CIN: L65910MH1992PLC067632**

**Email: info@veerhealthcare.net Website: www.veerhealthcare.net**

**NOTES:**

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30th May, 2025.
- 2 The above financial results are extracted from the Audited Financial Statements of the Company which are prepared in accordance with Indian Accounting Standards ('Ind AS') as prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder.
- 3 During the quarter and year ended March 31, 2025 the Company is operating in a single segment i.e. 'Healthcare Pharma Products'. Accordingly, segment wise reporting is not applicable.
- 4 The figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between audited figures in respect of full financial year and unaudited published year-to-date figures up to third quarter ended December 31, 2024 and December 31, 2023 respectively, which were subject to limited review.
- 5 The financial results of the Company are available at [www.bseindia.com](http://www.bseindia.com) and at [www.veerhealthcare.net](http://www.veerhealthcare.net).

Place: Mumbai  
Date: 30th May, 2025



For Veerhealth Care Limited

Yogesh M. Shah  
Chairman & Director  
DIN: 00169189

**VEERHEALTH CARE LIMITED**

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

**Statement of Assets and Liabilities**

(Amount in lakhs)

	Particulars	As at 31-03-2025 Audited	As at 31-03-2024 Audited
<b>A</b>	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	(a) Property Plant & Equipment	1987.00	1196.88
	(b) Capital work in progress	-	-
	(c) Investment Property	-	-
	(d) Intangible assets under development	-	-
	(e) Financial Assets		
	(i) Investments	-	-
	(ii) Loans	-	-
	(iii) Trade receivables	29.38	0.22
	(iv) Others	225.87	209.73
	(f) Deferred Tax Asset (Net)	-	-
	(g) Other Non-Current Assets	46.85	59.17
	<b>Total Non-Current Assets</b>	<b>2289.10</b>	<b>1466.00</b>
2	<b>Current Assets</b>		
	(a) Inventories	244.48	139.60
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	320.62	392.04
	(iii) Cash & cash equivalents	116.28	23.85
	(iv) Bank Balances other than (iii) above	-	-
	(v) Loans	234.72	739.82
	(vi) Others	-	-
	(c) Current Tax Assets (Net)	-	-
	(d) Other Current Assets	171.81	50.37
	<b>Total Current Assets</b>	<b>1087.91</b>	<b>1345.68</b>
	<b>TOTAL ASSETS</b>	<b>3377.01</b>	<b>2811.68</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Equity</b>		
	(a) Equity Share Capital	1999.85	1999.85
	(b) Other Equity	222.03	184.03
	<b>Total Equity</b>	<b>2221.88</b>	<b>2183.88</b>
2	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	419.90	-
	(ii) Trade Payables	-	-
	(b) Provisions	19.08	37.76
	(c) Deferred Tax Liabilities (net)	87.27	73.61
	(d) Other Non-Current Liabilities	272.86	239.12
	<b>Total Non-Current Liabilities</b>	<b>799.11</b>	<b>350.49</b>
3	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	70.91	-
	(ii) Trade Payables	261.97	215.51
	(iii) Other Financial Liabilities	-	-
	(b) Other Current Liabilities	7.65	28.59
	(c) Provisions	15.49	33.21
	<b>Total Current Liabilities</b>	<b>356.02</b>	<b>277.31</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>3377.01</b>	<b>2811.68</b>

By order of the Board  
For Veerhealth Care Limited



*[Signature]*

Yogesh M. Shah  
Chairman & Director  
DIN: 00169189

Place: Mumbai  
Date: 30th May, 2025

**VEERHEALTH CARE LIMITED**

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

**Cash Flow Statement for the year ended March 31, 2025**

(Amount in lakhs)

Particulars	Year ended March 31, 2025	Year ended March 31, 2024
<b>(A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit for the year	39.14	41.36
Adjustments for:		
Depreciation	90.78	71.15
Interest and finance charges	43.78	16.44
Tax expenses	22.96	87.54
Other Comprehensive Income	(1.14)	(0.76)
Other Adjustment	0.00	0.00
Interest income	(60.53)	(39.94)
<b>Operating profit before working capital changes</b>	<b>134.99</b>	<b>175.79</b>
Adjustments for changes in working capital:		
(Increase)/decrease in financial assets	(16.14)	2.97
(Increase)/decrease in other assets	(109.12)	37.20
(Increase)/decrease in inventories	(104.88)	120.97
(Increase)/decrease in trade receivables	42.26	(205.41)
Increase/(decrease) in provisions	(36.40)	33.21
Increase /(decrease) in trade payables	46.46	158.00
Increase /(decrease) in other non current liabilities	33.74	(16.38)
Increase /(decrease) in other current liabilities	(20.94)	11.73
<b>Cash generated from/(used in) operations</b>	<b>(30.03)</b>	<b>318.08</b>
Income taxes paid (net of refund)	(9.29)	(28.50)
<b>Net cash flow from /(used in) operating activities</b>	<b>(39.32)</b>	<b>289.58</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Payment for purchase of property, plant and equipment	(880.91)	(82.55)
Proceeds from sale of property, plant and equipment	0.00	15.10
Interest received	60.53	39.94
<b>Net cash flow from/(used in) investing activities</b>	<b>(820.38)</b>	<b>(27.51)</b>
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
(Payment)/Receipt of long term borrowings	419.90	0.00
Proceeds from loans	505.10	(583.02)
Proceeds/(repayment) from short term borrowings (net)	70.91	0.00
Additions in share capital	0.00	999.92
Net Increase in other equity	0.00	(999.92)
Interest and finance charges paid	(43.78)	(16.44)
<b>Net cash flow from financing activities</b>	<b>952.13</b>	<b>(599.46)</b>
<b>Net change in cash and cash equivalents (A+B+C)</b>	<b>92.43</b>	<b>(337.39)</b>
Cash and bank balances at the beginning of the year	23.85	361.24
Cash and bank balances at the end of the year	116.28	23.85



**INDEPENDENT AUDITOR'S REPORT**

**TO THE BOARD OF DIRECTORS OF Veerhealth care Limited**

**Report on the Audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone quarterly financial results of Veerhealth Care Limited ("the Company") for the quarter ended March 31, 2025 and the year to date results for the period from April 01, 2024 to March 31, 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in Indian Accounting Standard, prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with relevant rules issued thereunder, and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended March 31, 2025 as well as the year to date results for the period from April 01, 2024 to March 31, 2025.

**Basis for Opinion**


We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.



**Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

Attention is drawn to the fact that the figures for the quarter ended March 31, 2025 as reported in these standalone financial results are the balancing figures between audited figures in respect of the year ended on March 31, 2025 and the published year to date figures up to the end of the third quarter of the financial year. Also, the figures up to the end of the third quarter had only been reviewed and were not subjected to audit.

For Jayesh R Shah & Co.

Chartered Accountants

Firm Regn. No. 104182W

Jayesh Shah  
Proprietor

M. No. 033864

Place: Mumbai

Date: 30<sup>th</sup> May, 2025

UDIN: 25033864BMNRMW3072



Date: 30<sup>th</sup> May, 2025

To,  
**BSE Limited**  
Department of Corporate Services  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400001.  
**Scrip Code: 511523**

**Sub.: Declaration in respect of Audit Report with Unmodified Opinion pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm and declare that M/s. Jayesh R. Shah & Co., Statutory Auditors of the Company have issued Audit Report with unmodified opinion on standalone financial results of the Company for the financial year ended March 31, 2025.

Kindly take the above on record.

Thanking You.

Yours faithfully,  
For **Veerhealth Care Limited**

Yogesh M. Shah  
Chairman & Director  
DIN: 00169189

